Cargando...
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
Before a medicine can be recommended for a marketing authorization research must be provided to regulators that convincingly supports the benefit‐risk of the product in the claimed indication. The established criteria for such research are usually expressed in terms of evidence from randomized contr...
Gardado en:
| Publicado en: | Pharmacoepidemiol Drug Saf |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7687174/ https://ncbi.nlm.nih.gov/pubmed/32301230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.5005 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|